Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Teva Pharmaceutical Industries Limited is a global generic and specialty pharmaceutical manufacturer headquartered in Israel, producing medicines across CNS, respiratory, oncology, and other therapeutic areas. Investors research TEVA to understand exposure to the generic drug market, which faces pricing pressure but serves essential healthcare demand worldwide.
Get a full AI research report on TEVA
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Teva Pharmaceutical Industries Limited do?
Teva generates revenue by developing, manufacturing, and distributing generic medicines in multiple dosage forms, along with branded specialty drugs like COPAXONE (multiple sclerosis), AJOVY (migraine prevention), and AUSTEDO (tardive dyskinesia). The company also operates an active pharmaceutical ingredients (API) business and contract manufacturing services, creating diversified revenue streams across regulated markets in the US, Europe, Israel, and internationally. Generic pharmaceuticals typically operate on lower margins than branded drugs but benefit from high volume and reduced R&D costs once patents expire.
Bull case
- ✓Gross margin of 52.5% indicates strong pricing power and manufacturing efficiency in the generic and specialty drug portfolio.
- ✓Forward PE of 38.9 is substantially lower than trailing PE of 59.6, suggesting market expectations for earnings growth over the next 12 months.
- ✓PEG ratio of 0.96 indicates valuation may be reasonable relative to expected earnings growth, a consideration for growth-focused investors.
- ✓Diversified product portfolio spanning CNS, respiratory, oncology, and specialty injectables reduces dependence on any single therapeutic area or market.
- ✓Branded specialty drugs like COPAXONE and AJOVY provide higher-margin revenue streams less exposed to generic price compression.
Bear case
- ✗Debt-to-equity ratio of 217.8% signals very high financial leverage, limiting financial flexibility and increasing refinancing risk in rising rate environments.
- ✗Current ratio of 0.88 and quick ratio of 0.46 indicate potential near-term liquidity constraints, with current liabilities exceeding current assets.
- ✗Operating margin of 4.0% and net margin of 4.1% are thin, typical of generic pharma but leaving little room for operational setbacks or pricing pressure.
- ✗Return on equity of 9.7% is modest relative to the cost of capital, particularly given the company's high debt load and financial risk profile.
- ✗Generic drug pricing remains under structural pressure from healthcare cost containment, biosimilar competition, and regulatory price controls in major markets.
TEVA valuation & financial health
Teva trades at a trailing PE of 59.6 and forward PE of 38.9, with a PEG ratio of 0.96 suggesting the valuation may align with growth expectations. However, the company's financial health shows stress: a debt-to-equity ratio of 217.8% indicates heavy reliance on debt financing, while a current ratio of 0.88 and quick ratio of 0.46 raise liquidity concerns. Profitability metrics are modest—net margin of 4.1%, operating margin of 4.0%, and ROE of 9.7%—typical of the generic pharmaceutical sector but constrained by competitive pricing. The 52.5% gross margin demonstrates manufacturing and pricing strength, but leverage and working capital management appear to be material considerations for financial stability.
The bottom line
Teva operates in a mature, competitive generic pharmaceutical market with structural pricing headwinds, offset by essential global demand and a diversified product portfolio including higher-margin specialty drugs. Key factors to weigh include the company's substantial debt burden relative to earnings, tight liquidity position, and modest profitability margins against its gross margin strength and forward earnings growth expectations. Investors should monitor debt refinancing activity, generic price trends in key markets, and the performance of specialty branded drugs as indicators of financial trajectory. The valuation discount from trailing to forward PE suggests market participants are pricing in near-term earnings recovery, making execution on cost management and specialty drug sales critical to watch.
Frequently asked questions
What does Teva Pharmaceutical Industries Limited do?
Teva develops, manufactures, and distributes generic medicines, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally. The company operates across multiple therapeutic areas including CNS, respiratory, and oncology, serving patients in the US, Europe, Israel, and other markets.
Is TEVA a good stock to research?
TEVA is relevant for investors interested in generic pharmaceuticals, healthcare exposure, and companies with high debt leverage. Research should focus on debt management, liquidity, and competitive positioning in generic pricing markets rather than growth-stage characteristics.
Why is TEVA's debt-to-equity ratio so high?
Teva's 217.8% debt-to-equity ratio reflects significant debt accumulated from past acquisitions and operations in a capital-intensive, low-margin industry. High leverage limits financial flexibility and increases sensitivity to interest rate changes and refinancing risk.
What are TEVA's main profit drivers?
Teva's revenue comes from high-volume generic drug sales (lower margin but stable), specialty branded drugs like COPAXONE and AJOVY (higher margin), and contract manufacturing services. The 52.5% gross margin reflects manufacturing efficiency, though operating and net margins remain thin at 4.0% and 4.1% respectively.
Is TEVA overvalued at a PE of 59.6?
The trailing PE of 59.6 is elevated, but the forward PE of 38.9 and PEG ratio of 0.96 suggest the market is pricing in significant near-term earnings improvement. Whether this is justified depends on the company's ability to execute cost management and specialty drug sales growth.
What are the main risks for TEVA investors?
Key risks include high debt levels limiting financial flexibility, tight liquidity (current ratio 0.88), structural generic drug pricing pressure, biosimilar competition, and regulatory price controls in major markets. Financial stress could intensify if earnings decline or refinancing costs rise.
Research TEVA with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.